deltatrials
Completed PHASE1 INTERVENTIONAL 4-arm NCT02891980

A Safety Trial to Test MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers

A Phase I Trial to Utilize Systems Biology Approaches to Examine the Safety, Immunogenicity, and 'Omics Response to MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Conditions Ebola Disease Marburg Disease
Interventions Ad26 Zaire Ebola Vaccine MVA Multi-Filo Ebola Vaccine
Updated 19 times since 2017 Last updated: Jul 24, 2025 Started: Mar 24, 2017 Primary completion: Mar 21, 2019 Completion: Mar 21, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Ebola Disease and Marburg Disease, this trial is completed. The trial is conducted by National Institute of Allergy and Infectious Diseases (NIAID) and has accumulated 19 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Feb 2018 · 12 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Apr 2020 · 11 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Jul 2024 · 40 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshot~Jun 2025 – ~Aug 2025 · 2 months · monthly snapshot~Aug 2025 – present · 11 months · monthly snapshot

Change History

19 versions recorded

  1. Aug 2025 — Present [monthly]

    Completed PHASE1

  2. Jun 2025 — Aug 2025 [monthly]

    Completed PHASE1

  3. Sep 2024 — Jun 2025 [monthly]

    Completed PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  5. Mar 2021 — Jul 2024 [monthly]

    Completed PHASE1

▶ Show 14 earlier versions

  1. Jan 2021 — Mar 2021 [monthly]

    Completed PHASE1

  2. Apr 2020 — Jan 2021 [monthly]

    Completed PHASE1

  3. May 2019 — Apr 2020 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  4. Apr 2019 — May 2019 [monthly]

    Active Not Recruiting PHASE1

  5. Mar 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE1

  6. Feb 2019 — Mar 2019 [monthly]

    Active Not Recruiting PHASE1

  7. Jan 2019 — Feb 2019 [monthly]

    Active Not Recruiting PHASE1

  8. Dec 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE1

  9. Nov 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE1

  10. Oct 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE1

  11. Jun 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE1

  12. Feb 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

    Status: Not Yet Recruiting → Active Not Recruiting

  13. Feb 2017 — Feb 2018 [monthly]

    Not Yet Recruiting PHASE1

  14. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institute of Allergy and Infectious Diseases (NIAID)
Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations